Falanga A - Search Results

1

Low levels of ADAMTS-13 with high anti-ADAMTS-13 antibodies during remission of immune-mediated thrombotic thrombocytopenic purpura highly predict for disease relapse: A multi-institutional study.

Schieppati F, Russo L, Marchetti M, Barcella L, Cefis M, Gomez-Rosas P, Caldara G, Carpenedo M, D'Adda M, Rambaldi A, Savignano C, Billio A, Bruno Franco M, Toschi V, Falanga A. Schieppati F, et al. Among authors: falanga a. Am J Hematol. 2020 Aug;95(8):953-959. doi: 10.1002/ajh.25845. Epub 2020 May 21. Am J Hematol. 2020. PMID: 32350923 Free article.

2

Effect of all-trans-retinoic acid on the hypercoagulable state of patients with breast cancer.

Falanga A, Toma S, Marchetti M, Palumbo R, Raffo P, Consonni R, Marziali S, Dastoli G, Barbui T. Falanga A, et al. Am J Hematol. 2002 May;70(1):9-15. doi: 10.1002/ajh.10073. Am J Hematol. 2002. PMID: 11994976 Free article. Clinical Trial.

3

All-trans retinoic acid modulates microvascular endothelial cell hemostatic properties.

Marchetti M, Vignoli A, Bani MR, Balducci D, Barbui T, Falanga A. Marchetti M, et al. Among authors: falanga a. Haematologica. 2003 Aug;88(8):895-905. Haematologica. 2003. PMID: 12935977

4

All-trans-retinoic acid and bleeding/thrombosis.

Falanga A, Marchetti M, Barbui T. Falanga A, et al. Pathophysiol Haemost Thromb. 2003;33 Suppl 1:19-21. doi: 10.1159/000073283. Pathophysiol Haemost Thromb. 2003. PMID: 12954994 No abstract available.

5

Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera.

Falanga A, Marchetti M, Vignoli A, Balducci D, Barbui T. Falanga A, et al. Exp Hematol. 2005 May;33(5):523-30. doi: 10.1016/j.exphem.2005.01.015. Exp Hematol. 2005. PMID: 15850829 Free article.

6

Pathogenesis of thrombosis in essential thrombocythemia and polycythemia vera: the role of neutrophils.

Falanga A, Marchetti M, Barbui T, Smith CW. Falanga A, et al. Semin Hematol. 2005 Oct;42(4):239-47. doi: 10.1053/j.seminhematol.2005.05.023. Semin Hematol. 2005. PMID: 16210037 Review.

7

Clotting mechanisms and cancer: implications in thrombus formation and tumor progression.

Falanga A, Marchetti M, Vignoli A, Balducci D. Falanga A, et al. Clin Adv Hematol Oncol. 2003 Nov;1(11):673-8. Clin Adv Hematol Oncol. 2003. PMID: 16258469 Review.

8

Differential effect of the low-molecular-weight heparin, dalteparin, and unfractionated heparin on microvascular endothelial cell hemostatic properties.

Vignoli A, Marchetti M, Balducci D, Barbui T, Falanga A. Vignoli A, et al. Among authors: falanga a. Haematologica. 2006 Feb;91(2):207-14. Haematologica. 2006. PMID: 16461305

9

V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules.

Falanga A, Marchetti M, Vignoli A, Balducci D, Russo L, Guerini V, Barbui T. Falanga A, et al. Exp Hematol. 2007 May;35(5):702-11. doi: 10.1016/j.exphem.2007.01.053. Exp Hematol. 2007. PMID: 17577920 Free article.

10

Endothelial capillary tube formation and cell proliferation induced by tumor cells are affected by low molecular weight heparins and unfractionated heparin.

Marchetti M, Vignoli A, Russo L, Balducci D, Pagnoncelli M, Barbui T, Falanga A. Marchetti M, et al. Among authors: falanga a. Thromb Res. 2008;121(5):637-45. doi: 10.1016/j.thromres.2007.06.015. Epub 2007 Aug 10. Thromb Res. 2008. PMID: 17692905

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

524 results

Search Page

Filters